Article
A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
Annals of palliative medicine - 1 May 2021
Shan Chang-Guo, Wang Hui, Lin Tao, Liu Da, Wen Lei, Chen Zhi-Jie, Zhen Jun-Jie, Lai Ming-Yao, Zhang Lu, Zou Xiao, Hong Wei-Ping, Cai Lin-Bo
Abstract excerpt
Leptomeningeal metastasis (LM) is a rare but lethal complication of advanced non-small cell lung cancer (NSCLC) that has a devastating impact on patient survival and quality of life. Osimertinib, an irreversible tyrosine kinase inhibitor, is approved as a therapy for advanced NSCLC with epidermal growth factor receptor (EGFR) mutation. However, the efficacy and optimal dosage of osimertinib in the treatment of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.